Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to tr...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2020-03-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/vedolizumab-in-the-treatment-of-inflammatory-bowel-disease:-evolving-paradigms/ |
| _version_ | 1828264216752029696 |
|---|---|
| author | Benjamin Crooks Tom Barnes Jimmy K Limdi |
| author_facet | Benjamin Crooks Tom Barnes Jimmy K Limdi |
| author_sort | Benjamin Crooks |
| collection | DOAJ |
| description | Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to treat inflammatory bowel diseases. The GEMINI registrational trials established the efficacy of vedolizumab for the induction and maintenance of remission in both CD and UC, with the most favourable results in tumour necrosis factor (TNF)-antagonist-naive patients. In recent years, a wealth of ‘real-world’ data has emerged supporting positive clinical, endoscopic and histological outcomes in patients treated with vedolizumab (VDZ) as well as reassuring safety data. More recently, the results of the first head-to-head trials of VDZ and TNF antagonists have been reported, as well as the results of a number of studies exploring the role of therapeutic drug monitoring with VDZ. This review brings together data reported on VDZ to date, including from the GEMINI trials, real-world data and emerging studies regarding therapeutic drug monitoring and immunogenicity. The safety profile of VDZ is also reviewed. Evolving treatment paradigms are explored, including data regarding the role of VDZ in perianal CD, post-operative complications and recurrence, extraintestinal manifestations and pregnancy. |
| first_indexed | 2024-04-13T04:21:35Z |
| format | Article |
| id | doaj.art-af30bda4a9bf4834bea22e916bb4a7c6 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 1740-4398 |
| language | English |
| last_indexed | 2024-04-13T04:21:35Z |
| publishDate | 2020-03-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-af30bda4a9bf4834bea22e916bb4a7c62022-12-22T03:02:43ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-03-01911510.7573/dic.2019-10-2Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigmsBenjamin CrooksTom BarnesJimmy K LimdiInflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to treat inflammatory bowel diseases. The GEMINI registrational trials established the efficacy of vedolizumab for the induction and maintenance of remission in both CD and UC, with the most favourable results in tumour necrosis factor (TNF)-antagonist-naive patients. In recent years, a wealth of ‘real-world’ data has emerged supporting positive clinical, endoscopic and histological outcomes in patients treated with vedolizumab (VDZ) as well as reassuring safety data. More recently, the results of the first head-to-head trials of VDZ and TNF antagonists have been reported, as well as the results of a number of studies exploring the role of therapeutic drug monitoring with VDZ. This review brings together data reported on VDZ to date, including from the GEMINI trials, real-world data and emerging studies regarding therapeutic drug monitoring and immunogenicity. The safety profile of VDZ is also reviewed. Evolving treatment paradigms are explored, including data regarding the role of VDZ in perianal CD, post-operative complications and recurrence, extraintestinal manifestations and pregnancy.https://www.drugsincontext.com/vedolizumab-in-the-treatment-of-inflammatory-bowel-disease:-evolving-paradigms/crohn’s diseaseinflammatory bowel diseasesmucosal healingsafetytherapeutic drug monitoringulcerative colitisvedolizumab |
| spellingShingle | Benjamin Crooks Tom Barnes Jimmy K Limdi Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms Drugs in Context crohn’s disease inflammatory bowel diseases mucosal healing safety therapeutic drug monitoring ulcerative colitis vedolizumab |
| title | Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms |
| title_full | Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms |
| title_fullStr | Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms |
| title_full_unstemmed | Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms |
| title_short | Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms |
| title_sort | vedolizumab in the treatment of inflammatory bowel disease evolving paradigms |
| topic | crohn’s disease inflammatory bowel diseases mucosal healing safety therapeutic drug monitoring ulcerative colitis vedolizumab |
| url | https://www.drugsincontext.com/vedolizumab-in-the-treatment-of-inflammatory-bowel-disease:-evolving-paradigms/ |
| work_keys_str_mv | AT benjamincrooks vedolizumabinthetreatmentofinflammatoryboweldiseaseevolvingparadigms AT tombarnes vedolizumabinthetreatmentofinflammatoryboweldiseaseevolvingparadigms AT jimmyklimdi vedolizumabinthetreatmentofinflammatoryboweldiseaseevolvingparadigms |